Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- MEDIPAL HOLDINGS CORPORATIONMEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIBTOKYO & HYOGO, Japan, September 11, 2026--JCR and MEDIPAL announced that the first participant has been dosed in the global Phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB.
- GRWMichael Rasekhi Announces Scholarship Opportunity for Undergraduate Medical Students NationwideThe Michael Rasekhi Scholarship for Medical Students announces the opening of applications for this one-time educational scholarship designed to support undergraduate students pursuing a future in medicine. The opportunity invites eligible students to reflect on challenges facing modern healthcare and consider how their future careers can contribute to stronger, healthier communities.To view an enhanced version of this graphic,...
- GRWSheila Busheri Scholarship Announces New Opportunity for Undergraduate Students Pursuing Medical CareersThe Sheila Busheri Scholarship announces a new educational opportunity for undergraduate students pursuing medical careers and students enrolled in accredited medical schools. The scholarship supports aspiring healthcare professionals who demonstrate a commitment to improving healthcare access, advancing innovation, and serving underserved populations.To view an enhanced version of this graphic, please...
- GRWDr. Thanapoom Boonipat Announces Scholarship for Future Doctors to Support Undergraduate Medical Aspirants Across the USAThe Dr. Thanapoom Boonipat Scholarship for Future Doctors officially opens its application window today, inviting undergraduate students nationwide to apply for this prestigious one-time award. This initiative reflects the professional philosophy of Dr. Thanapoom Boonipat, who seeks to identify and support the next generation of physicians dedicated to excellence in patient care and medical innovation. The scholarship serves as a bridge for...
- GRWDr. Wael Sakr Launches Prestigious Scholarship to Support Future Physicians Across the United StatesThe Dr. Wael Sakr Scholarship for Medical Students officially opens its application period today, inviting undergraduate students nationwide to apply for a one-time financial award designed to support aspiring medical professionals. This initiative reflects the enduring commitment of Dr. Wael Sakr to medical education and the cultivation of the next generation of healthcare leaders. By removing financial barriers, the scholarship aims to...
- GRWDr. Lynn Puana Scholarship Advances Proactive Healthcare Thinking Among Future Medical ProfessionalsThe Dr. Lynn Puana Scholarship for Medical Students announces its current application opportunity for undergraduate and graduate students pursuing careers in healthcare and medical sciences. The scholarship recognizes academically accomplished students who demonstrate an interest in innovative medicine, cognitive health, integrative care, and approaches that place greater emphasis on prevention and early intervention.To view an enhanced...
- HmediumFrost & Sullivan Released the Global Digital and Intelligent Medical Imaging Ecosystem Development in the AGI Era White Paper 2026Frost & Sullivan has officially released the "Global Digital and Intelligent Medical Imaging Ecosystem Development in the AGI Era White Paper 2026". The White Paper systematically reviews the medical imaging ecosystem and examines how artificial intelligence (AI), medical imaging foundation models, and AI Agents are reshaping imaging services in the AGI era. It analyzes the medical imaging workflow, differentiated pain points across...
- Phio Pharmaceuticals Corp.Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceKing of Prussia, Pennsylvania--(September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL® siRNA gene-silencing technology designed to eliminate cancer, today announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York...
- Penguin AiPenguin Ai Launches Intelligent RCM, Bringing Its AI Workforce to the Revenue CycleAI workers help health systems and RCM companies prevent denials and recover revenue, showing the evidence behind every recommendation. — Penguin Ai, the company building an AI workforce for healthcare administration, today announced the...
- AcarixPeer-Reviewed Study Confirms CADScor System Can Diagnose Heart Failure With Far Fewer False Positives Than Standard Blood TestAalborg University-led research, published in PLOS Digital Health, found the CADScor System's acoustic sensing platform identified heart failure with diagnostic accuracy comparable to a leading blood test, and with significantly fewer false positives OKLAHOMA CITY, Sept. 11, 2026...
- Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical TrialClearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the enrollment of the first patients with Alcohol Use Disorder (“AUD”) in its ongoing clinical trial evaluating CMND-100, the Company’s proprietary psychedelic-based treatment candidate for AUD.
- GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, will host a live company presentation on the development of the TriKE® platform for cancer treatment today, September 11, 2026, at 2:00 p.m. Eastern Time.